History Of Our Anaplasmosis Vaccine
History Of Anaplasmosis Vaccine By D. Gene Luther, D.V.M., Ph.D.
Cellular # 225-266-8375

425 Woodstone Drive
Baton Rouge, LA 70808

Our Anaplasmosis Vaccine was developed at Louisiana State University, Agriculture Center's Veterinary Science Department by a team of three scientists. The research team was composed of L.T. Hart, Ph.D., W.J. Todd, Ph.D., and D. G. Luther, D.V.M., Ph.D. The research was done in the late 1980s and early 1990s. The study led to a patent for the process of separating the Anaplasma marginale initial bodies from the red blood cell antigens of bovine blood. A study of the purified Anaplasma marginale initial bodies and several different adjuvants was completed to see which product would provide protection for an infectious Anaplasmosis challenge in mature bovine. One adjuvant gave excellent protection against a virulent challenge and was selected the adjuvant to be used in our vaccine.

Louisiana State University licensed the Anaplasmosis Vaccine to Pitman-Moore. Pitman-Moore asked our research team to help them take the vaccine through the USDA licensing process. While the USDA efficacy and safety studies were ongoing Mallinckrodt bought Pitman-Moore. Mallinckrodt finished the USDA licensing process and marketed the vaccine for three years as Plazvax. Mallinckrodt was bought by Schering-Plough. Schering-Plough elected not to produce and market Plazvax. Schering-Plough's decision not to produce and market Plazvax resulted in no commercially available vaccine for Anaplasmosis.

Dairymen in Florida contacted Dr. Luther and asked if he could make the vaccine and he told them that he could but the USDA would not allow him to ship or sell the vaccine. They asked if Dr. Luther would make the vaccine for them if they could get USDA approval and Dr. Luther agreed to make the vaccine. The USDA approved the production and sale of the vaccine as an Experimental Anaplasmosis Vaccine to veterinarians in Florida. Since that time the USDA has approved the use of the vaccine in:
North Dakota,
South Carolina,
West Virginia,
Puerto Rico.

The vaccine is not licensed by the USDA but is approved for use as an Experimental Vaccine. USDA licensed vaccines have to be produced in a USDA licensed facility and that vaccine has to go through the USDA licensing procedure. There are no USDA licensed facilities in Louisiana. The Experimental Vaccine that we produce employs the same purification procedure as did Mallinckrodt's Plazvax. Our vaccine uses the same strain of Anaplasma marginale that was used in Plazvax. Our vaccine has provided good protection against Bovine Anaplasmosis in the United States and Puerto Rico. We have never had a case of Neonatal Isoerythrolysis reported in calves of vaccinated cows. The vaccine has been used in cows in all stages of pregnancy with no problems being reported.  The USDA has not carried out efficacy or potency test on this experimental vaccine.

We have marketed hundreds of thousands of doses of our Experimental Anaplasmosis Vaccine since early in 2000. To this point the only complaint we have had regarding the vaccine was the first vaccine was very thick and hard to use. The first vaccine we produced was mixed in an omni blender, which made it very thick. We have since homogenized the vaccine as did Mallinckrodt and it is now about the thickness of milk.

If you are interested in obtaining the vaccine, we would be pleased to discuss and answer any questions that you might have. We can be contacted by multiple means as stated at the top of this page.
E-mail D. Gene Luther, D.V.M., Ph.D.

University Products, L.L.C.
Donald G. Luther, D. V.M., Ph.D.
425 Woodstone Drive Baton Rouge, LA 70808
Dear Producers: Please read and follow. The 11 items below will help prevent the spread of Anaplasmosis, prevent waste and improve the efficiency of this vaccine.
1.  Our Anaplasmosis Vaccine is a 1 cc Dose to be given Subcutaneous in the Neck Only.

2.  It requires two doses the first year with one annual booster each year after the first year. The second dose should be given four weeks after the first dose. It takes time for the immune system to develop the immunity after the vaccination. The animal should get good protective immunity in a week to ten days after the second injection of vaccine.

3. The vaccine is a killed vaccine and it is stable at environmental temperatures. We do not ship the vaccine on ice.

4. The Vaccine in the vial is sterile until opened with a needle. Mold spores from the air will start to grow when the vaccine warms and will destroy the vaccine left in the vial. After a vial has been opened it should be stored in a refrigerator.
5.  A One cc (1cc) dose requires the use of a 3 cc syringe as larger syringes are not accurate enough to deliver a 1 cc dose. Using larger syringes will waste vaccine.
6. Place one sterile needle in the vial and remove all doses through this one needle; this should keep you from contaminating the vial with Anaplasma and transmitting the disease to other cows in the herd.
7. Use a sterile needle on each animal. When the needle is removed from the syringe if there is any sign of blood on the hub of the syringe, discard and use a sterile syringe. Not doing the above can result in you spreading Anaplasmosis as well as a number of other diseases to your susceptible animals. Needles and syringes can be washed and boiled or autoclaved for 20 minutes and then allowed to air dry, stored in a sterile place and then be safe to re-use.
8. If you suspect an animal is incubating Anaplasmosis when you are vaccinating the animal, you can inject them with
Tetracycline in another site and it will not affect the vaccine.
9. It is safe to use the vaccine in any stage of pregnancy. There has never been a reported case of Neonatal lsoerythrolysis (NI) in calves of vaccinated cows.
10. Be sure to observe your herd for signs of Anaplasmosis until the immune system has had time to develop the protection needed to prevent clinical cases of Anaplasmosis. Good protection should occur about 7 to 10 days after the second injection of vaccine.
11. No vaccine of any kind is 100 percent protective. Vaccine breaks are not always caused by the vaccine and are often the fault of the animal that receives the vaccine. See below for some of the causes for vaccine breaks.
There are many strains of Anaplasmosis in the USA and even more strains in the World. Our vaccine utilizes the
Anaplasmosis Mississippi Strain of Anaplasma marginale. The Mississippi strain appears to cross protect against most, if not all, of the Anaplasma Strains in the USA as well as many other parts of the World.
For any vaccine to give protection, the animal getting vaccine must have a healthy immune system. Old animals may
have a compromised immune system and not respond to any vaccine. Younger animals can have compromised immune systems from some diseases and especially from some viral diseases and they will not respond to the Antigens in the
Our vaccine is dispensed aseptically into sterile vials. Approximately 10% overfill above the stated dosage is included in each vial. This extra volume is allocated for priming of the recommended 3 cc syringe.

Printable PDF of Vaccine Insert